

# **Recent Advances in Lupus Nephritis**

Essay submitted for partial fulfillment of master degree  
in internal medicine

By

***Nader Atef Rizkalla***

M.B.B.Ch

Faculty of Medicine-Ain shams university

Under supervision of

***Prof.Dr. Eman Ahmed Hafez***

Professor of Internal Medicine and Rheumatology

Faculty of Medicine-Ain shams university

***Prof.Dr.Howaida Elsayed Mansour***

Professor of Internal Medicine and Rheumatology

Faculty of Medicine-Ain shams university

***Dr.Reem Abdel Moniem Habeeb***

Assistant Professor of Internal Medicine and Rheumatology

Faculty of Medicine-Ain shams university

*Cairo 2011*

## CHAPTER 1

# *Systemic Lupus Erythematosus*

## CHAPTER 2

### *Lupus Nephritis*

## CHAPTER 3

# *Updated Management in Lupus Nephritis*

*Summary*

## References

*Introduction and*

*Aim of the Work*

# 3 Ì~VÁ'èæXbVø6 VÄj dVp| oY

رسالة توطئة للحصول علي درجة الماجستير في أمراض الباطنة العامة  
مقدمة من

الطبيب/ نادر عاطف رزق الله  
بكالوريوس الطب والجراحة  
جامعة عين شمس

œ\üç h †  
ز.Àu €Σ ]< μ ]K&A  
أستاذ الباطنة العامة و الروماتيزم  
كلية الطب- جامعة عين شمس

œ †€ ç ä ¶]çœœ K&A  
استاذ الباطنة العامة و الروماتيزم  
كلية الطب- جامعة عين شمس

g Ífu < √†]ç ç ÊKJA  
استاذ مساعد الباطنة العامة و الروماتيزم  
كلية الطب- جامعة عين شمس

كلية الطب  
جامعة عين شمس

---

## *Contents*

| <b>Title</b>                                           | <b>Page</b> |
|--------------------------------------------------------|-------------|
| • <b>Contents .....</b>                                | <b>I</b>    |
| • <b>Acknowledgement .....</b>                         | <b>II</b>   |
| • <b>List of Tables .....</b>                          | <b>III</b>  |
| • <b>List of Figures.....</b>                          | <b>IV</b>   |
| • <b>List of Abbreviations .....</b>                   | <b>V</b>    |
| • <b><u>Introduction and Aim of the Work</u> .....</b> | <b>1</b>    |
| • <b><u>Chapter 1:</u></b>                             |             |
| <b>Systemic Lupus Erythematosus.....</b>               | <b>5</b>    |
| • <b><u>Chapter 2:</u></b>                             |             |
| <b>Lupus nephritis .....</b>                           | <b>42</b>   |
| • <b><u>Chapter 3:</u></b>                             |             |
| <b>Updated management in lupus nephritis.....</b>      | <b>63</b>   |
| • <b>Summary .....</b>                                 | <b>102</b>  |
| • <b>References .....</b>                              | <b>105</b>  |
| • <b>Arabic Summary</b>                                |             |

---

## *Acknowledgement*

Thanks to Allah for the strength and insistence that I was given during the achievement of this work.

I find no words by which I express my thankfulness, gratitude and appreciation to ***Prof.Dr. Eman Ahmed Hafez*** Professor of Internal Medicine and Rheumatology , Faculty of Medicine Ain Shams University, for her support, guidance, advice, generous help and encouragement during supervising this work.

I would like to express my extreme appreciation and thanks to ***Prof.Dr. Howaida Elsayed Mansour*** Professor of Internal Medicine and Rheumatology , Faculty of Medicine Ain Shams University, for her great support and valuable unlimited help and supervision throughout the work.

Also ***Dr. Reem Abdel Moniem Habeeb***, Assistant Professor of Internal Medicine and Rheumatology for her guidance, precious advice and continuous support, in every step in this work

---

## *List of Tables*

| <b>Tab. No</b>           | <b>Subjects</b>                                                                                                             | <b>Page</b> |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------|-------------|
| <b>Table (1-1)</b>       | <b><i>American College of Rheumatology Criteria for the Classification of SLE</i></b>                                       | <b>11</b>   |
| <b>Table (1-2):</b>      | <b><i>Frequency of Clinical Symptoms of SLE</i></b>                                                                         | <b>13</b>   |
| <b>Table (1-3 )</b>      | <b><i>Neuropsychiatric manifestations of systemic lupus erythematosus</i></b>                                               | <b>22</b>   |
| <b>Table (1-4):</b>      | <b><i>Show commonly Abnormal Tests on Body Fluids in SLE</i></b>                                                            | <b>26</b>   |
| <b>Table (1-5) shows</b> | <b><i>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)</i></b>                                                  | <b>31</b>   |
| <b>Table (1-6) :</b>     | <b><i>Comparison of the Different Disease Activity Indices</i></b>                                                          | <b>36</b>   |
| <b>Table (1-7).</b>      | <b><i>The Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for SLE.</i></b> | <b>40</b>   |
| <b>Table (2-1):</b>      | <b><i>International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification of lupus nephritis</i></b>  | <b>46</b>   |
| <b>Table (2- 2):</b>     | <b><i>Abnormal Urinary Findings in LN</i></b>                                                                               | <b>55</b>   |
| <b>Table (2-3):</b>      | <b><i>National Institute of Health version of activity and chronicity indices in LN</i></b>                                 | <b>61</b>   |
| <b>Table (2-4):</b>      | <b><i>Characteristic Features and Clinicopathological Correlations in Lupus Nephritis.</i></b>                              | <b>62</b>   |
| <b>Table (3-1):</b>      | <b><i>WHO Classification and treatment of lupus nephritis</i></b>                                                           | <b>63</b>   |
| <b>Table (3-2):</b>      | <b><i>The prognostic factors of lupus nephritis</i></b>                                                                     | <b>98</b>   |
| <b>Table (3-3):</b>      | <b><i>additional factors to consider during pregnancy with LN</i></b>                                                       | <b>101</b>  |

---

## *List of Figures*

| <b>Fig. No</b>     | <b>Subjects</b>                                                | <b>Page</b> |
|--------------------|----------------------------------------------------------------|-------------|
| <b>Fig. (2-1):</b> | <b>Schematic representation of a model for pathogenesis LN</b> | <b>45</b>   |
| <b>Fig. (2-2):</b> | <b>Lupus nephritis class II</b>                                | <b>47</b>   |
| <b>Fig. (2-3):</b> | <b>Lupus nephritis class III (A)</b>                           | <b>48</b>   |
| <b>Fig. (2-4):</b> | <b>Lupus nephritis Class IV-G (A)</b>                          | <b>49</b>   |
| <b>Fig. (2-5):</b> | <b>Lupus nephritis Class IV-G (A/C)</b>                        | <b>49</b>   |
| <b>Fig. (2-6):</b> | <b>Lupus nephritis class V</b>                                 | <b>50</b>   |
| <b>Fig. (2-7):</b> | <b>Lupus nephritis Class VI</b>                                | <b>51</b>   |

---

## *List of Abbreviations*

|       |                                          |
|-------|------------------------------------------|
| aCA   | Anticardiolipin Antibodies               |
| ACE   | Angiotensin Converting Enzyme            |
| ACLE  | Acute Cutaneous Lupus Erythematosus      |
| ACR   | American College of Rheumatology         |
| AI    | Activity Index                           |
| ALMS  | Aspreva Lupus Management Study           |
| ANA   | Antinuclear Antibodies                   |
| ANC   | Absolute Neutrophil Count                |
| APCs  | Antigen Presenting Cells                 |
| aPL   | Antiphospholipid Antibodies              |
| APS   | Antiphospholipid Syndrome                |
| APTT  | Activated Partial Thromboplastin Time    |
| ARA   | American Rheumatism Association          |
| ARB   | Angiotensin II Receptor Blocker          |
| AZA   | Azathioprine                             |
| BILAG | British Isles Lupus Assessment Group     |
| BUN   | Blood Urea Nitrogen                      |
| C     | Complement                               |
| CAD   | Coronary Artery Disease                  |
| CAP   | College of American Pathologists         |
| CBC   | Complete Blood Count                     |
| CCLE  | Chronic Cutaneous Lupus Erythematosus.   |
| CI    | Chronicity Index                         |
| CMV   | Cytomegalo virus                         |
| CNS   | Central Nervous System,                  |
| CRP   | C-reactive Protein                       |
| CRP   | C-reactive protein                       |
| CS    | Corticosteroids                          |
| CsA   | Cyclosporine A                           |
| CSF   | Cerebrospinal Fluid                      |
| CYC   | Cyclophosphamide                         |
| DDLE  | Disseminated Discoid Lupus Erythematosus |
| DI    | Damage Index                             |
| DLE   | Discoid Lupus Erythematosus              |
| DPLN  | Diffuse Proliferative Lupus Nephritis    |
| DPLN  | Diffuse Proliferative Lupus Nephritis.   |
| Drvt  | Dilute russell viper venom time          |
| dsDNA | Double Stranded DNA                      |
| DVT   | Deep Vein Thrombosis                     |

---

---

|        |                                                  |
|--------|--------------------------------------------------|
| EBV    | Epstein Barr virus                               |
| ECLAM  | European Consensus Lupus Activity Measure        |
| ESR    | Erythrocyte Sedimentation Rate                   |
| ESRD   | End-stage Renal Disease                          |
| FANA   | Fluorescent Antinuclear Antibody                 |
| FPLN   | Focal Proliferative Lupus Nephritis              |
| GBM    | Glomerular Basement Membrane                     |
| GFR    | Glomerular Filtration Rate                       |
| GMCSF  | Granulocyte-Macrophage Colony-Stimulating Factor |
| HLA    | Human Leucocyte Antigen                          |
| ICs    | Immune Complexes                                 |
| IL     | Interleukins                                     |
| INF    | Interferon                                       |
| ISN    | International Society of Nephrology              |
| ISN    | International Society of Nephrology              |
| ITP    | Idiopathic Thrombocytopenic Purpura              |
| KCT    | Kaolin Clotting Time                             |
| LA     | Lupus Anticoagulant                              |
| LAI    | Lupus Activity Index                             |
| LDH    | Lactate Dehydrogenase                            |
| LDL    | Low De                                           |
| LN     | Lupus Nephritis                                  |
| LN     | Lupus Nephritis                                  |
| LPL    | Lipoprotein Lipase                               |
| MHL    | Major Histocompatibility Complex                 |
| MLN    | Membranous Lupus Nephritis                       |
| MMF    | Mycophenolate Mofetil                            |
| MP     | Methylprednisolone                               |
| NIH    | National Institutes of Health                    |
| NPSLE  | Neuropsychiatric Lupus                           |
| NSAIDs | Non-Steroidal Anti-Inflammatory Drugs            |
| PE     | Pulmonary Embolism                               |
| PGA    | Physician's Global Assessment                    |
| PIH    | Pregnancy Induced Hypertension                   |
| PLN    | Proliferative Lupus Nephritis                    |
| PLN    | Proliferative Lupus Nephritis                    |
| RNP    | Antibody to ribonucleoprotein                    |
| RPS    | Renal Pathology Society                          |
| RPS    | Renal Pathology Society                          |
| RVT    | Renal Vein Thrombosis                            |
| SCLE   | Subacute Cutaneous Lupus Erythematosus.          |

---

---

|        |                                                                |
|--------|----------------------------------------------------------------|
| SELENA | Safety of Estrogens in Lupus Erythematosus National Assessment |
| SLAM   | Systemic Lupus Activity Measure                                |
| SLAM   | Systemic Lupus Activity Measure                                |
| SLE    | Systemic lupus erythematosus                                   |
| SLEDAI | Systemic Lupus Erythematosus Disease Activity Index            |
| SLICC  | Systemic Lupus International Collaborating Clinics             |
| Sm     | Smith Antigen                                                  |
| TMA    | Thrombotic Microangiopathic Hemolytic Anemia                   |
| TNF    | Tumor Necrosis Factor                                          |
| TTP    | Thrombotic Thrombocytopenic Purpura                            |
| UVL    | Ultra Violet Light                                             |
| VAS    | Visual Analogue Scale                                          |
| WBC    | White Blood Cell                                               |
| WHO    | World Health Organization                                      |